Clinical bottom line
Janus kinase (JAK) inhibitors represent an emerging class of targeted therapies for autoimmune and inflammatory diseases, offering novel immunomodulatory mechanisms. However, their use is associated with an increased risk of infections, particularly herpes zoster and opportunistic bacterial infections. Clinicians should maintain heightened vigilance for infectious complications in patients receiving JAK inhibitors, balancing immunosuppressive benefits against infection risks. Current evidence supports proactive infection risk assessment, vaccination strategies, and individualized monitoring, though definitive clinical guidelines remain evolving.
What the evidence shows
JAK inhibitors modulate intracellular signaling pathways critical to immune responses, which can impair host defense against pathogens (Gavegnano et al., 2020). This immunomodulation predisposes patients to infections, with herpes zoster reactivation being notably prevalent in patients treated for ulcerative colitis and other autoimmune conditions (Colombel et al., 2018). The mechanism involves interference with interferon signaling and T-cell function, which are essential for viral control.
Beyond viral infections, bacterial infections, including serious and opportunistic types, have been reported in patients receiving JAK inhibitors (Winthrop et al., 2008). Although much of the early infection risk data derives from anti-TNF and other biologic therapies, emerging reports indicate that JAK inhibitors share overlapping infection profiles, including pulmonary bacterial infections common in systemic autoimmune diseases (Handbook of Systemic Autoimmune Diseases, 2020). The risk appears influenced by underlying disease activity, concomitant immunosuppressants, and patient comorbidities.
The complexity of infection risk prediction is underscored by findings in related immunosuppressive therapies, where traditional risk factors and adverse event histories poorly predict infections (Besada et al., 2016). Occult infections may also contribute to clinical deterioration in patients on biologics, suggesting the need for thorough baseline screening and ongoing surveillance (Alkoky et al., 2018).
Molecular insights into JAK-STAT pathway inhibition provide a rationale for targeted therapies but also highlight potential vulnerabilities in antiviral and antibacterial immunity (Idborg et al., 2015). These mechanistic data reinforce the clinical observations of increased infection susceptibility and guide the development of personalized therapeutic approaches.
Caveats and uncertainty
The evidence base for infection risks specifically attributable to JAK inhibitors remains limited by relatively short post-marketing follow-up and heterogeneous patient populations. Much infection risk data is extrapolated from studies of other biologic agents or from observational registries with variable reporting standards (Winthrop et al., 2008). The relative contribution of JAK inhibition versus underlying disease or concomitant therapies to infection risk is challenging to disentangle.
Herpes zoster risk appears elevated but varies by indication, dose, and patient factors, and optimal prevention strategies, including vaccination timing and efficacy in immunosuppressed hosts, require further study (Colombel et al., 2018). Similarly, the spectrum and incidence of bacterial infections in JAK inhibitor recipients are not fully characterized, and the role of latent or subclinical infections remains incompletely understood (Alkoky et al., 2018).
Current clinical guidelines for infection monitoring and prophylaxis in JAK inhibitor-treated patients are evolving, with no universally accepted protocols. The balance between immunosuppression and infection risk necessitates individualized clinical judgment, pending more robust prospective data.
How this may change practice
Clinicians managing patients with autoimmune and inflammatory diseases on JAK inhibitors should incorporate infection risk assessment into routine care. This includes baseline screening for latent infections, consideration of herpes zoster vaccination prior to therapy initiation, and patient education regarding early signs of infection (Colombel et al., 2018).
Close monitoring during therapy for bacterial and viral infections is warranted, with a low threshold for diagnostic evaluation and treatment. Coordination with infectious disease specialists may be beneficial for complex cases or those with recurrent infections. Awareness of the unique immunologic effects of JAK inhibitors can inform risk stratification and guide decisions on concomitant immunosuppressive regimens.
Future practice may integrate personalized infection risk models based on molecular and clinical parameters, improving safety and therapeutic outcomes (Idborg et al., 2015). Until then, cautious clinical vigilance and adherence to emerging evidence-based recommendations remain paramount.